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1. Background
Although somatic mutations in the Janus kinase 2 gene (JAK2) occur in many Philadelphia-­‐
chromosome negative chronic myeloproliferative neoplasms (PN-­‐MPNs), disease evolution,
distinct phenotypes and the continuous clinical evidence of an increasing number of cases, with
younger patients affected, have been pointing to a growing involvement of environmental
factors in the pathogenesis of these diseases.
Several single nucleotide polymorphisms (SNPs), influencing DNA repair capacity and apoptotic
status, confer genetic predisposition to disease and determine therapeutic response. Moreover,
despite the development of more efficient drugs in the last years, some patients with PN-­‐MPNs
still evolve to myelodisplasia, myelofibrosis and acute leukaemia, conditions more difficult to
treat, with an incidence of 10% following certain types of chemotherapy and 2-­‐3% without
treatmentwith cytotoxic agents.
Genetic polymorphisms encoding apoptotic proteins are candidates for association with PN-­‐
MPNs, since apoptosis is a high regulated process in carcinogenesis.
We	  intend	  to	  evaluate	  the	  role	  of	  apoptosis	  SNPs	  in	  PN-­‐MPNs	  susceptibility.
2.Objectives
Our results revealed that for ET patients and when they are women and JAK2 positive, there is a
significant increased risk when carrying at least one variant allele for CASP9_rs1132312 (C653T)
polymorphism.
Haplogroup association studies didn’t allowed us to stablish a global haplogroup, but the
correlation for SNPs of CASP9 gene showed a decreased risk for two haplogroups (GCC and
GTT); a similar effect was obtained when effector caspases were grouped.
Although larger studies are required to confirm these results and to provide conclusive evidence
of association between these and other apoptosis variants and PN-­‐MPNs susceptibility, these
new data may contribute to a best knowledge of the pathophysiology of these disorders and, in
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We performed a case-­‐control study in 133 Caucasian Portuguese PN-­‐MPNs patients and 281
matched controls. All SNPs included in this study: rs1045485 and rs1035142 (CASP8), rs1052576,
rs2308950, rs1132312 and rs1052571 (CASP9), rs2227309 and rs2227310 (CASP7) and
rs13006529 (CASP10) were genotyped using real-­‐time PCR (RT-­‐PCR 7300 Applied Biosystem),
through TaqMan® SNP genotyping assays (Life Technology), according to manufacturer
instruactions. Differences in genotype frequency, smoking status, age class, gender, therapeutic
and pathology distributions between patients and controls were evaluated using SPSS 22.0
(SPSS Inc.).
3.Methods
When considered individually, none of the studied apoptosis polymorphisms is associated with
PN-­‐MPNs risk. No significant difference was found between the case and control groups
concerning age distribution, gender, smoking habits or genotype frequencies (Table 1). However,
alcohol consumption is significantly increased in patients, when compared to control group
(Table 1). Patients distribution by diagnosis was 80 (60.2%) with ET, 39 (29.3%) with PV and 14
(10.5%) with PMF. After stratification by pathology diagnosis our results showed (Table 2) a
significant increased risk for patients diagnosed with ET when present at least one variant allele
(T) for CASP9_rs1132312 (C653T) polymorphism (heterozygous individuals OR 2.300 CI95%
[1.180 – 4.484], Pvalue=0.014; combination of heterozygous with homozygous for variant allele
OR 2.203 CI95% [1.163 – 4.176], Pvalue=0.015). The same effect was found, after stratification by
gender in women (OR 4.370 CI95% [1.608 – 11.873], Pvalue=0.004) and also in those patients
who present JAK2 mutation (OR 2.886 CI95% [1.303 – 6.393], Pvalue=0.009) (Table 2).
Analyzing the results as haplogroup analysis, we only could establish a positively haplogroup for
CASP9 gene correlatedwith a decrease risk for PN-­‐MPNs (Table 3).
Concerning the number of SNPs of different genes under study, and grouping the effector
caspases genes as a hole, we stablish a new haplogroup (Table 4).
4. Results































































































































a	  Age	  of	  diagnosis	  for	  cases
































































a	  ORs	  were	  adjusted	  for	  age	  (30-­‐49,	  50-­‐69	  and	  	  ≥70),	  smoking	  status	  (never	  and	  current)
b The	  individuals	  with	  C/C	  genotype	  were	  considered	  as	  reference	   class
*	  P Crude	  and	  P Adjusted	  <	  0.02
Table	  1 – General	  characteristics	  for	  the	  PN-­‐MPNs	  cases	  (n=133)	  and	  control	  
population	  (n=281).
Table	  2 – ORs	  (95%	  CI)	  for	  CASP9 (Phe136Phe)	  polymorphism	  and	  PN-­‐MPNs	  
association.
Haplogroup association	  response
CASP8 CASP9 CASP10 OR	  crude
(95%	  CI)
P
















































Table	  4 – Haplogroup association	  response	  for	  SNPs	  present	  in	  all	  effector	  
caspases studied.
Table	  3 – Haplogroup association	  response	  for	  SNPs	  of	  CASP9	  gene.
